Korea Comirnaty Post-marketing Surveillance
← catalyst calendarNCT05032976 · readout in 158 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
12,000estimated
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-03-18 | actual | When the study began enrolling |
| Primary completion | 2027-01-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-24 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- COVID-19
- Vaccines
- Adverse Effects
- SARS-CoV-2
- Safety
Interventions
- Biological: Tozinameran 12 Years of age and older
- Biological: Tozinameran 5 to 11 Years of age
- Biological: Tozinameran 6 months to 4 years of age
- Biological: Riltozinameran 12 Years of age and older
- Biological: Famtozinameran 12 Years of age and older
- Biological: Famtozinameran 5 to 11 Years of age
- Biological: Raxtozinameran 12 years of age and older
- Biological: Raxtozinameran 6 months to 4 years of age
Primary outcomes
what the primary-completion date above is the date OFNumber of subjects with Solicited adverse events
measured 1 week after administration of BNT162b2 products
Number of subjects with Unsolicited adverse events
measured 28 days after administration of BNT162b2 products
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed